QuickVue SARS Antigen FIA Dipstick
(25 Tests per Kit)
* Free Next Day Air when you buy 5 or more kits!
Current stock Expires March 2024. No Returns or Exchanges!
Note: Free shipping applies only to 48 continental USA states and additional fees may be required for Hawaii, Alaska, Puerto Rico and other outlying areas.
You can be contacted after check out for additional fees. You may contact us at ord[email protected] for formal quotation outside continental USA.
|New Tiered Pricing||Quantity Required||Price per Kit|
|Tier 1||1 - 4 Kits||$175.00 per Kit|
|Tier 2||5 - 9 Kits||$162.50 per Kit|
|Tier 3||10+ Kits||$149.75 per Kit|
QuickVue SARS Antigen FIA Dipstick, Nasal Swab.
The QuickVue SARS Antigen Test is a lateral flow immunoassay that allows for the rapid, qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in anterior nares (NS) swab specimens directly from individuals who are suspected of COVID-19 by their healthcare provider within the first five days of the onset of symptoms.
The QuickVue SARS Antigen test is intended for use by trained clinical laboratory personnel and individuals trained in point of care settings. The QuickVue SARS Antigen test is only for use under the Food and Drug Administration’s Emergency Use Authorization.
- For use under the Emergency Use Authorization (EUA) only
- For in vitro diagnostic use
- Rx Only
All EUA authorized COVID-19 products are non-returnable with no exceptions unless damaged in transit, product is recalled for manufacturer erformacne issues or deemed defective by the manufacturer. Buyer should beware that EUA authorized products could be revoked by FDA and removed from authorization list. Products that are revoked are non-returnable and non-refundable. Note: Manufacturer recalls are returnable for replacement product only. No Cash refund will be given for manufacturer-initiated recall.
* REQUIRED FIELDS IN ORDER TO PURCHASE
All clinical specimens must be at room temperature before beginning the assay.
Performing the assay outside the time and temperature ranges provided may produce invalid results.
Assays not performed within the established time and temperature ranges must be repeated.
Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
The QuickVue SARS Antigen test does not differentiate between SARS-CoV and SARS-CoV-2.
Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen. Antigen is generally detectable in anterior nares specimens during the acute phase of infection.